Tiankang: CKBA Cream Receives Approval Notice for Clinical Trials of Drugs

"Tai'enkang Announcement: A subsidiary, Jiangsu Bochuangyuan Biomedical Technology Co., Ltd., has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving the seamless adaptive clinical trial of CKBA cream for the indication of acne rosacea in Phase II/III. CKBA cream is a locally developed topical formulation with unique characteristics such as being classified as a Class 1 innovative drug, having a new structure, independent intellectual property rights, clear mechanism of action, and good safety profile. The company will soon initiate the seamless adaptive clinical trial of CKBA cream for the indication of acne rosacea in Phase II/III. If the product is approved for market entry, it is expected to provide patients with innovative and safe and effective treatment options, thus holding significant social value and economic importance."